Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)

Number of Women With Clinical Cure as a Measure of Efficacy

Number of women with clinical cure as determined by absence of BV by the Amsel's criteria

Time frame: Day 9-12

Number of Women With Nugent Cure as a Measure of Efficacy

Number of women with Nugent cure, defined as a Nugent score 0-3 (normal flora), when a score of 7-10 (BV flora) was determined at Baseline.

Time frame: Day 9-30

Patient Perceived Symptom Resolution as a Measure of Efficacy (Odor)

Number of women with absence of patient-reported vaginal odor, as determined by responses in a symptom questionnaire as to whether or not they had vaginal odor.

Time frame: Day 9-30

Incidence of Genital Adverse Events Potentially Related to Treatment

Number of women who experience signs/symptoms of genital irritation potentially related to treatment, by solicited reporting of specific AEs as a measure of safety.

Time frame: For the duration of the study (up to Visit Day 21-30)